Skip to content

PolitiKit

Lobbying by Merck Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Merck Canada Inc.

Meetings this Parliament
58
With MPs
11
Since Nov 2021
117
Active registrations
1

Most recent reported meeting: Sep 30, 2026.

Registrations in effect

In-house (corporation) In effect since Aug 25, 2026

Filed by David D. Jones, PRESIDENT

Lobbyists

  • David D. Jones · PRESIDENT
  • Jannie Oosthuizen · EVP, Oncology & MSD International
  • Jean-Philippe D’Aoust · Associate Director, Policy and Government Relations
  • Jennifer Chan · Vice President, Policy & Communications
  • Octavio Rego · Dir, Key Account Management, Policy & Ext Affairs - Quebec/Atlantic
  • Philippe Houle · Executive Director Policy & Government Affairs
  • Sandra Wainwright · Director - Regulatory Affairs
  • Sean Kinney · Associate Director - Patient Access

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Fisheries and Oceans Canada (DFO), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Office of the Information Commissioner of Canada (OIC), Office of the Privacy Commissioner of Canada (OPC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Senate of Canada, Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (33)
  • Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
  • Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes.
  • Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussed
  • Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).
  • World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG).
  • US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
  • The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
  • Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations.
  • Smart Regulations as it relates to the biopharmaceutical industry.
  • Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits.
  • Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization.
  • Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services.
  • Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
  • Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
  • Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
  • Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products.
  • Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
  • Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health.
  • New Substances Notification Regulations as it relates to the biopharmaceutical industry.
  • National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
  • Income Tax Act as it relates to biopharmaceutical products.
  • Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.
  • Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
  • Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
  • Federal Government involvement in national strategies to address major chronic diseases having a significant burden on the Canadian health care system, such as Dementia, Diabetes, Hepatitis C and Cancer and major public health concerns such as Antimicrobial resistant.
  • Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
  • Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
  • Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).
  • Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
  • Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
  • Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
  • Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs.
  • Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.

Registration 959141-12241-54. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by David D. Jones (63), Marwan Akar (54).

  • Reported by David D. Jones · In-house (corporation)

    • David K Lee · Chief Regulatory Officer, Innovation, Science and Economic Development Canada (ISED)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussed Read more

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Klara Hupel · Regional Advisor (Quebec), Innovation, Science and Economic Development Canada (ISED)
    • Michael Paramathasan · Director of Policy & Legislative Affairs, Innovation, Science and Economic Development Canada (ISED)
    Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Read more

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Matthew Hall · Sen Policy Advisor, Prime Minister's Office (PMO)
    Federal Government involvement in national strategies to address major chronic diseases having a significant burden on the Canadian health care system, such as Dementia, Diabetes, Hepatitis C and Cancer and major public health concerns such as Antimicrobial resistant. Read more

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Miro Froehlich · Dir Policy, Privy Council Office (PCO)
    • Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
    Federal Government involvement in national strategies to address major chronic diseases having a significant burden on the Canadian health care system, such as Dementia, Diabetes, Hepatitis C and Cancer and major public health concerns such as Antimicrobial resistant. Read more

    Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Manuela Tomic · Minister of Foreign Affairs, Global Affairs Canada (GAC)
    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Read more

    Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Jay Allen · Minister Economic, Global Affairs Canada (GAC)
    Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP). Read more

    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.

    Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Christopher Rose · CONSULTATION AND ACCOMMODATION UNIT, Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Ed Morgan · POLICY, PLANNING AND INTERNATIONAL AFFAIRS DIRECTORATE, Health Canada (HC)
    • david k lee · Assistant Deputy Minister, Health Canada (HC)
    and 1 more
    • alysha Croker · POLICY, PLANNING AND INTERNATIONAL AFFAIRS DIRECTORATE, Health Canada (HC)
    Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies. Read more

    Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.

    Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.

    Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Read more

    New Substances Notification Regulations as it relates to the biopharmaceutical industry.

    The government's Science and Technology strategy as it relates to the biopharmaceutical industry.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Read more

    Federal Government involvement in national strategies to address major chronic diseases having a significant burden on the Canadian health care system, such as Dementia, Diabetes, Hepatitis C and Cancer and major public health concerns such as Antimicrobial resistant.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    Economic DevelopmentHealthResearch and Development

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Nick Kang · Senior policy Director, Prime Minister's Office (PMO)
    • Yash Nanda · Policy Advisor, Finance Canada (FIN)
    • Jessica Fullerton · Policy advisor, Prime Minister's Office (PMO)

    Economic DevelopmentHealthResearch and Development

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Helena Jaczek · Member of House of Commons
    • Chris Forbes · Deputy Minister, Finance Canada (FIN)
    • Kim Pate · Honorable Senate, Senate of Canada

    Economic DevelopmentHealthResearch and Development

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Lindsay Mell · Senior Policy Advisor, Health Canada (HC)

    Health

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    HealthIndustryResearch and Development

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    HealthIndustryResearch and Development

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Stephen Ellis · Member of Parliament, House of Commons

    HealthIndustryResearch and Development

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Marilou McPhedran · Senator, Senate of Canada

    HealthIndustryResearch and Development

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)

    IndustryResearch and Development

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)

    IndustryResearch and DevelopmentScience and Technology

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • F. Gigi Osler · Senate of Canada, Senate of Canada
    • Mohamad Iqbal Ravalia · Honorable Senator, Senate of Canada

    HealthIndustry

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Simon Kennedy · Office of Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    Economic DevelopmentHealthIndustry

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Corey Tochor · Member of Parliament
    • sharon burey · Honorable Senator, Senate of Canada
    • Christopher Evelyn · MInsiter of Families, Employment and Social Development Canada (ESDC)
    • Connor MacDonald · Policy Advisor, House of Commons
    and 1 more
    • Anton Lori · Party Leader, House of Commons

    HealthIndustry

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Valerie Bradford · Member of Parliament, House of Commons
    • Chandra Arya · Member of House of Commons, House of Commons
    • Yash Nanda · Policy Advisor, Finance Canada (FIN)
    • Stephen Ellis · Member house of Commons, House of Commons

    Health

    Official report

  • Reported by Marwan Akar · In-house (corporation)

    • Alan Thom · Sr Manager, Vaccine Supply and Assurance, Public Health Agency of Canada (PHAC)
    • Milan Patel · Director, Vaccine Supply & Assurance, Public Health Agency of Canada (PHAC)
    • Michael Pignat · Manager, Procurement, Public Health Agency of Canada (PHAC)
    • David Hennigar · Senior Policy Analyst, Public Health Agency of Canada (PHAC)

    HealthIndustry

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.